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Pediatric drug development has been chal-
lenging for more than 5 decades. Two recent 
books; one a workshop report and the other 
a volume prepared from the perspective of 
the pharmaceutical industry offer mod-
est hope that clinical therapeutics within 
this vulnerable population is beginning 
to be addressed. Both unfortunately focus 
predominantly on pediatric drug develop-
ment within the US, however, parallel activ-
ity within the World Health Organization 
(WHO) offers hope that pediatric drug 
development will improve in both developed 
and developing countries (see the WHO 
website for more information http://www.
who.int/mediacentre/factsheets/fs341/en/
index.html, accessed 25 August 2010).
The Institute of Medicine’s (IOM) 
Forum on Drug Discovery, Development 
and Translation held a workshop in 2006 
to explore issues in pediatric drug devel-
opment. Topics addressed included; regula-
tory framework, challenges in developing 
and prescribing drugs, models for enhanc-
ing pediatric drug development and chal-
lenges and opportunities for the future. 
Several legislative activities have stimu-
lated pediatric drug development in the 
United States beginning with the Food and 
Drug Administration Modernization Act, 
Best Pharmaceuticals for Children Act and 
Pediatric Research Equity Act. Despite the 
recent legislative, regulatory and research 
activity in the US and Europe, barriers to 
pediatric drug development are  substantial, 
and the workshop identified many of them. 
See the following web sites for current 
information:
US NIH: http://bpca.nichd.nih.gov/
FDA: http://www.fda.gov/ScienceRe-
search/SpecialTopics/PediatricTherapeu-
ticsResearch/default.htm
EMEA: http://www.ema.europa.eu/ema/ 
index . j sp?cur l=pages/spec ia l_top -
ics/general/general_content_000302.
jsp&murl=menus/special_topics/special_
topics.jsp&mid=WC0b01ac058002d4ea
DG Research: http://imi.europa.eu/
index_en.html
Published after the IOM report is a volume 
with potential solutions to some of the chal-
lenges identified by the IOM Forum. While 
pediatric pharmacology began in earnest 
in the late 1960s, the struggle to place drug 
development for infants, children, and youth 
on the same footing as adult drug develop-
ment remains far from satisfactory. The 
editors of Pediatric Drug Development have 
created a volume which reviews earlier work 
in pediatric pharmacology while providing 
a resource for learning about pediatric drug 
development from a pharmaceutical industry 
perspective. They summarize the history of 
pediatric drug development, explore ethical 
aspects, describe regulatory environments, 
and then consider the traditional steps in 
drug development: preclinical evaluation, 
clinical studies across the diverse ages and 
developmental stages. The two final sections 
focus on manufacturing and case studies.
Past, Present, and future of 
Pediatric drug develoPment
There is a substantial burden of childhood 
diseases for which there are no approved 
drugs, representing an opportunity for drug 
development. However, this burden of unmet 
healthcare is often at odds with the low prior-
ity of children for health care resources. The 
consequence of the low priority of children 
is that globally about 3/4ths of drugs do not 
carry regulatory approval for use in infants, 
children or youth; 2/3 of medications used 
in children in the US are used off label, in 
Europe about half and in Japan less than 20% 
of package inserts have sufficient information 
for treating infants, children, or youth.
ethical underPinnings
While US legislation encourages pediatric 
drug development, there are differences 
between NIH and FDA guidelines for exclud-
ing infants, children, and youth from clinical 
trials. The ethical complexity grows as the 
age of the child decreases, and unfortunately 
most clinical trials in neonates have insuffi-
cient numbers of subjects for adequate evalu-
ation of the therapy under consideration.
Within pediatric clinical trials, the issues 
surrounding use of placebo and equipoise 
deserves special attention. Further chal-
lenges include the complexity of parental 
permission and parental understanding 
of the clinical study in which their child is 
participating. Globally, the issue of ethics 
becomes more challenging, however, this is 
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differ, as noted above in the discussion of 
the CNS, cardiovascular and renal systems. 
An additional constraint in pediatric stud-
ies are the volumes of blood or other media 
removed for these analyses. Use of innova-
tive non-invasive approaches is encour-
aged, as are surrogate endpoints and patient 
reported outcomes.
formulation, chemistry, and 
manufacturing controls
Pediatric friendly formulations remains 
a vexing issue for drug development. 
Interestingly the European pediatric drug 
legislation may offer a pathway to enhance 
pediatric formulations by providing 8 years 
of data protection and 10 years of marketing 
protection.
case studies successes for 
children
The book ends with several case studies.
summary
Over the past 5 decades there have been 
advances in pediatric drug development; 
understanding of pk and pd have improved, 
attention to regulatory and ethical issues has 
advanced so that more pediatric trials have 
been conducted. Despite this progress much 
remains to do, and part of the path for-
ward is outlined in these two books. Those 
interested in pediatric drug development 
from the perspective of the pharmaceuti-
cal industry should review both volumes 
as they will find them useful resources for 
teaching, research and all other relevant 
aspects of pediatric drug development.
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systems, most attention has been given to the 
consequences of drugs on the developing 
central nervous system and brain. Of special 
interest is the broad period of  vulnerability – 
beginning in utero and extending into late 
adolescence or early adulthood. This broad 
window of vulnerability makes it difficult 
to collect human data on safety and efficacy, 
implying the need for drug development and 
regulatory activity to rely on animal models, in 
vitro data and computational approaches.
Consideration of the cardiovascular 
system points out gaps in routine pediatric 
data; for example what are normal blood 
pressures and how should they be meas-
ured? Similarly, data collected by the pedi-
atric ECG needs validation; lead placement 
and sampling frequency are important, 
automated ECG algorithms developed in 
adults may have little utility in children.
The kidney plays important roles in 
determining elimination and reabsorption 
of drugs as well as being a target for drug 
action. However, much remains to be done 
to understand developmental stage changes 
in glomerular filtration, tubular secretion, 
and reabsorption.
clinical trial oPerations and 
good clinical trials
Emerging discussions on ethics in pedi-
atric trials is the informed consent proc-
ess for conduct of pediatric trials. Parents 
can provide informed permission, but are 
both parents required to provide informed 
permission? In addition to parental permis-
sion the assent of the child must be sought, 
dependent on age or developmental state 
of the child. Long term studies, necessary 
to fully understand efficacy and safety may 
require consent/assent/permission at multi-
ple time points. Part and parcel with consent 
are the processes for recruitment and reten-
tion, with special attention to the potential 
for coercion, especially where families have 
limited health care resources.
clinical efficacy and safety 
endPoints
Across the course of development the end-
points used to assess safety and efficacy can 
a critical  component of drug development 
because most pediatric clinical trials occur in 
an international context, in multiple coun-
tries with many different ethics systems.
regulatory guidelines for 
Pediatric drug develoPment: 
stimulation of Pediatric drug 
research by regulatory 
authorities
While there are many similarities between US 
and EU regulatory guidelines, there remain 
important and critical differences. European 
legislation involves both country and EU spe-
cific guidelines. Within Japan the off-license 
or unlabeled use of drugs in children is as 
common as in the US and EU, however, there 
is no pediatric legislation, although there are 
efforts to develop such legislation.
Preclinical safety assessment
Preclinical assessment, for both efficacy and 
safety, is a critical area as is clear from the 
missteps in assuming pediatric safety can be 
extrapolated from adult studies. Industry 
and regulatory bodies are currently work-
ing to define preclinical safety methodology, 
but much remains to be done.
Pharmacological PrinciPles in 
Pediatric drug develoPment
One domain in which pediatric pharmacol-
ogy has been successful, is alerting industry 
and regulatory bodies to developmental dif-
ferences in absorption, distribution, metab-
olism, and elimination. This knowledge is 
well summarized in sections dealing with 
hepatic pharmacology, pharmacogenom-
ics, and population pharmacokinetics and 
sparse sampling.
clinical trial oPerations 
differences between Pediatric 
and adult study subjects – 
develoPment issues related to 
organ develoPment and endPoint 
choices
The essential component of childhood is 
growth and development, understanding 
its stages and vulnerabilities is crucial for 
 pediatric drug development. Among all organ 
